Greek
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
European Neurology 2004

New-onset seizures after liver transplantation: clinical implications and prognosis in survivors.

Μόνο εγγεγραμμένοι χρήστες μπορούν να μεταφράσουν άρθρα
Σύνδεση εγγραφή
Ο σύνδεσμος αποθηκεύεται στο πρόχειρο
Eun Jung Choi
Joong Koo Kang
Sang Ahm Lee
Ki Hun Kim
Sung Gyu Lee
Frederick Andermann

Λέξεις-κλειδιά

Αφηρημένη

OBJECTIVE

To identify the probable etiologies and characteristics of new-onset seizures after orthotopic liver transplantation (OLT) and to assess their clinical implications and prognosis.

METHODS

We retrospectively analyzed the clinical, electrophysiologic and laboratory data of 17 patients with new-onset seizures after OLT among 367 adult and pediatric patients who underwent OLT between 1999 and 2001.

RESULTS

A suspected etiology of seizures was identified in most patients, including 6 (35.2%) with neurotoxicity due to immunosuppressive therapy, 4 (23.5%) with cerebrovascular disease, 3 (17.6%) with severe metabolic derangement by sepsis or rejection, and 1 each (5.8%) with hyperglycemia and brain edema due to fulminant hepatic failure. Causative factors could not be identified in 2 patients (11.8%). Seizures recurred in 15 patients (88.2%), with 9 occurring on the same day as the original seizure. Attacks caused by neurotoxicity tended to have an earlier onset, within 1 week in 4 of 6 patients, than those caused by cerebrovascular disease and sepsis/rejection, but this was not statistically significant. A total of 21 EEGs were performed in 13 patients. Eleven patients had abnormal EEG findings, of whom 4 (30.7%) showed epileptiform discharges, but the outcome of patients with epileptiform activity did not differ statistically from that of patients without such discharges (p > 0.6). The incidence of poor outcome (death or persistent vegetative state) in the group with seizures was almost 10 times higher than in the group without seizures (52.9 vs. 5.7%, p < 0.001). The prognosis of patients with seizures due to cerebrovascular disease and severe metabolic derangement by sepsis/rejection was poorer than that of patients with seizures caused by the neurotoxicity of immunosuppressive drugs (p < 0.02), suggesting that the underlying cause of seizures is important in determining prognosis. Of 8 patients who survived, 1 was lost to follow-up. The long-term outcome of seizures in surviving patients was excellent, with all survivors available for follow-up being seizure-free for a mean follow-up of 42.5 months (range, 16-58 months).

CONCLUSIONS

New-onset seizures after OLT may herald fatal outcome, especially in patients with cerebrovascular disease or sepsis. The prognosis of seizures in survivors is excellent, and long-term antiepileptic drugs are not required in most cases.

Γίνετε μέλος της σελίδας
μας στο facebook

Η πληρέστερη βάση δεδομένων φαρμακευτικών βοτάνων που υποστηρίζεται από την επιστήμη

  • Λειτουργεί σε 55 γλώσσες
  • Βοτανικές θεραπείες που υποστηρίζονται από την επιστήμη
  • Αναγνώριση βοτάνων με εικόνα
  • Διαδραστικός χάρτης GPS - ετικέτα βότανα στην τοποθεσία (σύντομα)
  • Διαβάστε επιστημονικές δημοσιεύσεις που σχετίζονται με την αναζήτησή σας
  • Αναζήτηση φαρμακευτικών βοτάνων με τα αποτελέσματά τους
  • Οργανώστε τα ενδιαφέροντά σας και μείνετε ενημερωμένοι με την έρευνα ειδήσεων, τις κλινικές δοκιμές και τα διπλώματα ευρεσιτεχνίας

Πληκτρολογήστε ένα σύμπτωμα ή μια ασθένεια και διαβάστε για βότανα που μπορεί να βοηθήσουν, πληκτρολογήστε ένα βότανο και δείτε ασθένειες και συμπτώματα κατά των οποίων χρησιμοποιείται.
* Όλες οι πληροφορίες βασίζονται σε δημοσιευμένη επιστημονική έρευνα

Google Play badgeApp Store badge